Logo
x

Search

Subscribe Now

NewAmsterdam

NewAmsterdam Entered into an Exclusive License Agreement with Menarini Group to Commercialize Obicetrapib for Cardiovascular Diseases in EU

NewAmsterdam Entered into an Exclusive License Agreement with Menarini Group to Commercialize Obicetrapib for Cardiovascular Disea...

  • June 29, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.